Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01526837 : Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
PhasePhase 1
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

1. Recurrent Glioblastoma

2. At least 12 weeks expected survival (KPS >60)

3. 18 years of age or older

4. Able and willing to participate

Exclusion Criteria:

1. Any prior diagnosis of any other cancer or other concurrent malignancy.

2. Planned use or current use of other investigation therapy.

3. Systemic autoimmune disease

4. HIV positive

5. Concurrent life threatening disease

6. Impaired organ function

7. Active infection

8. Inadequately controlled hypertension

9. Congestive heart failure

10. Myocardial infection/unstable angina within 6 months

11. Stroke within 6 months

12. Pheripheral vascular disease

13. History of abdominal fistula/gastrointestinal performation

14. Non-healing wound

15. Coagulation disease

16. Known allergy to study treatments

17. Pregnant or lactating
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01526837      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740